Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 7/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | CCR8 | P51685 | 1/20 | 0.41 |
| ▸ | METAP1 | P53582 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16031834 | 0.90 | ALDH1A1 (0.40) | DRD4ALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL659325 | 0.87 | KDM4E (0.48) | DRD4ALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL900225 | 0.87 | — | — | |
| SCHEMBL29448519 | 0.87 | — | — | |
| SCHEMBL1481510 | 0.83 | ALDH1A1 (0.50) | DRD4ALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL1515110 | 0.83 | ALDH1A1 (0.46) | DRD4ALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL30853689 | 0.81 | ALDH1A1 (0.50) | DRD4ALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL29507637 | 0.81 | ALDH1A1 (0.50) | DRD4ALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL2056505 | 0.81 | ALDH1A1 (0.50) | DRD4ALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL29742285 | 0.81 | ALDH1A1 (0.50) | DRD4ALDH1A1MAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111377818-A | (meth) acrylate compound, polymer, resist material, and method for producing (meth) acrylate compound | 捷恩智株式会社 | 2020-07-07 | — | — | CN | claimed |
| US-5849764-A | Antagonists of gonadotropin releasing hormone | MERCK & CO., INC. (US) | 1998-12-15 | — | — | US | claimed |
| EP-3719028-B1 | IRIDIUM COMPLEX COMPOUND, COMPOSITION CONTAINING SAID COMPOUND AND SOLVENT, ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING SAID COMPOUND, DISPLAY DEVICE AND ILLUMINATION DEVICE | MITSUBISHI CHEM CORP (JP) | 2024-06-12 | — | — | EP | disclosed |
| EP-4383238-A2 | IRIDIUM COMPLEX COMPOUND, COMPOSITION CONTAINING THE COMPOUND AND SOLVENT, ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THE COMPOUND, DISPLAY DEVICE, AND ILLUMINATION DEVICE | Mitsubishi Chemical Corporation (JP) | 2024-06-12 | — | — | EP | disclosed |
| CN-113853381-B | Iridium complex compound, composition containing the compound and solvent, organic electroluminescent element containing the compound, display device and lighting device | 三菱化学株式会社 | 2024-06-11 | — | — | CN | disclosed |
| CN-111263766-B | Iridium complex compound, composition containing the compound and solvent, organic electroluminescent element containing the compound, display device and lighting device | 三菱化学株式会社 | 2024-04-02 | — | — | CN | disclosed |
| WO-2024004963-A1 | ORGANIC ELECTROLUMINESCENT LIGHT-EMITTING ELEMENT MATERIAL, ORGANIC ELECTROLUMINESCENT LIGHT-EMITTING ELEMENT, ORGANIC EL DISPLAY DEVICE, ORGANIC EL LIGHTING, ORGANIC ELECTROLUMINESCENT LIGHT-EMITTING ELEMENT-FORMING COMPOSITION, AND METHOD FOR PRODUCING ORGANIC ELECTROLUMINESCENT LIGHT-EMITTING ELEMENT | 三菱ケミカル株式会社 | 2024-01-04 | — | — | WO | disclosed |
| WO-2024004964-A1 | ORGANIC ELECTROLUMINESCENT ELEMENT, ORGANIC EL DISPLAY DEVICE, ORGANIC EL LIGHTING, AND METHOD FOR MANUFACTURING ORGANIC ELECTROLUMINESCENT ELEMENT | 三菱ケミカル株式会社 | 2024-01-04 | — | — | WO | disclosed |
| WO-2023182184-A1 | LIGHT-EMITTING LAYER COMPOSITION, ORGANIC ELECTROLUMINESCENT ELEMENT, AND PRODUCTION METHOD THEREFOR | 三菱ケミカル株式会社 | 2023-09-28 | — | — | WO | disclosed |
| CN-116685592-A | Composition for forming light-emitting layer of organic electroluminescent element, organic EL display device, and organic EL illumination | 三菱化学株式会社 | 2023-09-01 | — | — | CN | disclosed |
| CN-116655702-A | Iridium complex compound and composition containing the same and solvent | 三菱化学株式会社 | 2023-08-29 | — | — | CN | disclosed |
| CN-111263766-A | Iridium complex compound, composition containing iridium complex compound and solvent, organic electroluminescent element containing iridium complex compound, display device, and lighting device | 三菱化学株式会社 | 2020-06-09 | — | — | CN | disclosed |
| EP-1415986-B1 | SPIRO ISOBENZOFURANES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | BANYU PHARMA CO LTD (JP) | 2009-04-08 | — | — | EP | disclosed |
| US-7205417-B2 | Spiro compounds | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-04-17 | — | — | US | disclosed |
| EP-1622870-A2 | GLUTAMINYL BASED DP IV-INHIBITORS | Prosidion Ltd. (GB) | 2006-02-08 | — | — | EP | disclosed |
| US-20040259890-A1 | Spiro compounds | MSD K.K. (JP) | 2004-12-23 | — | — | US | disclosed |
| WO-2004099134-A2 | GLUTAMINYL BASED DP IV-INHIBITORS | PROSIDION LTD. (GB) | 2004-11-18 | — | — | WO | disclosed |
| US-20040229848-A1 | Glutaminyl based DP IV-inhibitors | PROSIDION LIMITED (GB) | 2004-11-18 | — | — | US | disclosed |
| CN-1538956-A | Spiro compounds | ������ҩ��ʽ���� | 2004-10-20 | — | — | CN | disclosed |
| EP-1415986-A1 | SPIRO COMPOUNDS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229848-A1 | Glutaminyl based DP IV-inhibitors | DPP4, DPP3, DNPEP | DRD4 1180/4885ALDH1A1 1262/4885MAPT 4201/4885 |
| US-20040259890-A1 | Spiro compounds | OPRD1, PER2, OPRK1 | DRD4 187/4885ALDH1A1 1250/4885MAPT 1752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.